AstraZeneca presented the project of a new global research center and headquarters of the company in Cambridge, UK. The project was presented in the framework of public hearings before applying for the construction works in the fall of 2014, the Start of construction is planned for the beginning 2015, the Plan of construction of the new object in territory of Cambridge biomedical campus includes the global centre, the centre of research activities, as well as the energy center. Main characteristics of the object: <ul><li>Priority science - tech laboratory will be separated from the rest working rooms glass walls, thus creating the effect of "visible science". This will allow to maintain the emphasis on the scientific innovation in the activities of all personnel, both in the scientific research departments and other departments. </li> <li>Support to joint work on object will be presented a number of open spaces and public access, which will contribute to the joint work not only in the framework of AstraZeneca, but also within the larger scientific community Cambridge biomedical campus and beyond. </li><li>a reflection of the character of the city - the unique characteristics of the historic centre of Cambridge has influenced the shape of the buildings. The centre will be a low-rise building with a courtyard reminiscent of the building of the Cambridge University colleges. </li><li>Under advanced environmental standards - AstraZeneca plans to get "Excellent" (Excellent) by the standards of BREAAM to your new place, laboratories which apply best practices in energy efficiency design. Also on the object will be set to the largest in Europe heat pump surface type, as in most parts of the object area will be established "green roofs". </li></ul> Mene Pangalos, Executive Vice-President, Innovative drugs (opening early stage of development), AstraZeneca, commented: "We are delighted to present a plan for the creation of our new facility in Cambridge. Our goal is to create an open, dynamic and opposite to the work of the centre, which will inspire our team and partners for expanding the boundaries of scientific innovative activity". The new center will combine the research activity of AstraZeneca, carried out in the areas of small molecules and biologics. This will provide the opportunity to explore the great potential of the combined application of biological preparations and small molecules. Cambridge biomedical campus will become a new base in the UK for research in the field of biological products and protein engineering, conducted by "MedImmune" (MedImmune), a unit of AstraZeneca, a leading activity in the field of biological preparations. About 500 employees already working in the division "MedImmune in Grant Park, located in the South-East of the city. "Through our combined portfolio of projects "AstraZeneca" and "MedImmune" we have already received a unique opportunity to investigate the potential of combination therapy to change ways to treat patients," said Dr. Bahia Jalal, Executive Vice President of the company "MedImmune". - In our new Global research center in Cambridge scientists from AstraZeneca and MedImmune" will work hand in hand over the development of science in our core therapeutic areas. This will help us maintain and strengthen the focus on the combined use of the experience and knowledge within our business to develop new methods of treatment and meet their medical needs in areas such as, for example, Oncology". In anticipation of the launch of the new object at the end of 2016, about 70 employees AstraZeneca already started working on temporary objects in Cambridge in Melbourne science Park, Cambridge science Park and Grant Park. By the end of 2014, approximately 300-400 employees AstraZeneca will be moved to Cambridge in order to strengthen relations with representatives of the Cambridge community of scientists-biologists. About company AstraZeneca AstraZeneca is an international innovative biopharmaceutical company focused on the research, development and commercial use of prescription drugs in such therapeutic areas as cardiology, Oncology, respiratory diseases and inflammation, infection, and psychiatry. The company is represented in more than 100 countries of the world, and its innovative medicines for millions of patients.